

Supplementary materials

Table of contents

Text S1: English translation of the questionnaire	2
Table S1: Characteristics of the invited persons, stratified by participation status	19
Table S2: Characteristics of participants, stratified by participation	20
Table S3: Risk differences for post-acute symptoms reported after six, nine or twelve months, comparison of SARS-CoV-2 test-positive and test-negative participants	21
Table S5: Risk differences of health problems after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group	29
Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group	31
Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued	32
Figure S1: Risk differences of symptoms around the test date, comparing SARS-CoV-2 test-positive and test-negative participants	33
Figure S2: Risk differences of symptoms 6-12 months after test, comparing hospitalized and non-hospitalized SARS-CoV-2 test-positive participants	34
Figure S3: Risk differences self-reported health problems with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group	35
Figure S4: Risk differences self-reported diagnoses with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group	36

Text S1: English translation of the questionnaire

Background information: This is a print of an electronic questionnaire containing activations. This means that when filling out the questionnaire electronically, it depends on test status and/or answers to previous questions, which questions a given participant will be asked next. In this print, activations will be indicated by explanatory text in square brackets. When send out to participants, their specific test date of reference, were inserted in all places indicated by [*test date*]. In one some questions, the listed time intervals differed depending on whether participants received the questionnaire 6, 9 or 12 month after the test. In this example, the intervals for at 6 months are shown.

[*Start page in the questionnaire*]

Welcome to the EFTER-COVID baseline questionnaire

In the EFTER-COVID project, we are examining the health of the population during and after the coronavirus pandemic. **Your answers are important, regardless of whether you have tested positive or negative for coronavirus (COVID-19)**

Everyone invited to participate in the study has been randomly selected to receive a questionnaire with a particular focus on a certain area of their health. The questionnaire you have received focuses on physical symptoms.

Many thanks for your help.

[*Test-positive participants only*]:

These first questions are about how you have been since you tested positive at [*testdate*]

Which of the following conditions best describes how you were when you were at your worst?

Think about the period from a week before you tested positive until 4 weeks after.

- (1) I had no symptoms
- (2) I was ill at home
- (3) I was hospitalised due to COVID-19
- (4) I was hospitalised due to COVID-19 and was intubated with a ventilator
- (5) I was hospitalised for reasons other than COVID-19

[*Test-positive participants only*]:

Did you take any of the following types of medication for your COVID-19 symptoms?

Think of the period from one week before you were tested at [*test date*] and until 4 weeks after.

- (1) Painkillers/antipyretics
- (2) Asthma medication
- (3) Other - please specify _____
- (4) I didn't take any medication

[Test-negative participants only]:

Why were you tested on the [test date]?

- (1) I had symptoms
- (2) I was a close contact of someone infected
- (3) I suspected that I had been exposed to the infection
- (4) Other
- (5) I can't remember

Physical symptoms in the period around the test.

Have you at any point had any of the following symptoms? Please consider the period from the week leading up to your test on [test date] and until now.


Kindly mark all the symptoms you have had without considering the symptom cause. You can add further comments at the end of the questionnaire.

	Yes	No	Don't know
Fever	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Chills	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Hot flushes / sweating	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Headache	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Muscle or joint pain	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Fatigue or exhaustion	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Dizziness	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Red or watery eyes	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Runny or stuffy nose	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>

Continued from previous page: In the week leading up to the test on [test date], and until now, did you have any of the following symptoms?

Kindly mark all the symptoms you have had without considering the symptom cause. You can add further comments at the end of the questionnaire.

	Yes	No	Don't know
Reduced or altered sense of smell	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced or altered sense of taste	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Cough	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Sore throat or pain when swallowing	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Shortness of breath	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Chest pain	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Nausea or vomiting	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Diarrhoea	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Abdominal pain	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced or loss of appetite	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced arm and leg strength	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Sleeping or tingling sensation, or other abnormal sensations in the legs and arms	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Other symptoms	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>



[In this question, only lines related to symptoms, which the participants have replied “yes” to in the previous question are displayed]

During which periods did you have symptoms?

“Around the test date” covers the period from a week before the test on [test date] and up to four weeks after.

Please mark all of the periods during which you have had the symptom. If you have trouble remembering, then please mark the periods to the best of your ability.

	Around the test date	1-2 months following the test	2-6 months following the test	The past 14 days
Fever	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Chills	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Hot flushes / sweating	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Headache	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Muscle or joint pain	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Fatigue or exhaustion	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Dizziness	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Red or watery eyes	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Runny or stuffy nose	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Reduced or altered sense of smell	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>

Reduced or altered sense of taste	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Sore throat or pain when swallowing	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Cough	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Shortness of breath	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Chest pain	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Nausea or vomiting	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Diarrhoea	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Abdominal pain	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Reduced or loss of appetite	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Reduced arm and leg strength	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>
Sleeping or tingling sensation, or other abnormal sensations in the legs and arms	(1) <input type="checkbox"/>	(12) <input type="checkbox"/>	(26) <input type="checkbox"/>	(14) <input type="checkbox"/>

[Only participants, who replied “yes” to having had fever]:

Did you take your temperature when you had a fever in the period around your test on the [test date]?

- (1) Yes (please write the highest temperature taken in the box below) _____
(0) No
(99) Don't know/Can't remember

[Only participants, who replied “yes” to having had fever]:

Were there known/probable causes other than COVID-19 for you having a fever in the period around the test on [test date]?

- (1) Yes (please explain in the box below) _____
(0) No
(99) Don't know

[In this question, only lines related to symptoms, which the participants have replied “yes” to having experienced, will be displayed]

Before the test on [test date], did you generally (i.e. often or chronically) suffer from any of the following physical symptoms?

	Yes	No	Don't know
Fever	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Chills	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Hot flushes / sweating	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Headache	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Muscle or joint pain	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Fatigue or exhaustion	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Dizziness	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Red or watery eyes	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>

Runny or stuffy nose	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced or altered sense of smell	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced or altered sense of taste	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Sore throat or pain when swallowing	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Cough	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Shortness of breath	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Chest pain	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Nausea or vomiting	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Diarrhoea	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Abdominal pain	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced or loss of appetite	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Reduced arm and leg strength	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Sleeping or tingling sensation, or other abnormal sensations in the legs and arms	(1) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>

[Only participants, who replied “yes” to having had headache. Only lines representing time intervals, where participants indicated having headache are displayed]:

How severe were your headaches when you were at your worst during the specified period(s)?

	No pain	Mild pain	Moderate pain	Strong pain	Unbearable pain
Generally before the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
Around the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
1-2 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
2-6 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
The past 14 days	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>

[Only participants, who replied “yes” to having had muscle or joint pain. Only lines representing time intervals, where participants indicated having this are displayed]:

How bad was your muscle or joint pain in the specified period(s)?

	No pain	Mild pain	Moderate pain	Strong pain	Unbearable pain
Generally before the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
Around the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
1-2 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
2-6 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
The past 14 days	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>

[Only participants, who replied “yes” to having had reduced or changed sense of smell. Only lines representing time intervals, where participants indicated having this are displayed]:

How was your sense of smell in the specified period(s), compared to normal?

My sense of smell was/is...

	Slightly reduced	Very reduced	Completely gone	Changed	Don't know
Generally before the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
Around the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
1-2 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
2-6 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
The past 14 days	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>

[Only participants, who replied “yes” to having had reduced or changed sense of taste. Only lines representing time intervals, where participants indicated having this are displayed]:

How was your sense of taste in the specified period(s), compared to normal?

My sense of taste was/is...

	Slightly reduced	Very reduced	Completely gone	Changed	Don't know
Generally before the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
Around the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>
1-2 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>

2-6 months following the test (1) (2) (3) (4) (5)

The past 14 days (1) (2) (3) (4) (5)

[Only participants, who replied “yes” to having experienced shortness of breath. Only lines representing time intervals, where participants indicated having this are displayed]:

Choose the following statement below that best describes your shortness of breath during the relevant period(s).

A. I only become short of breath when I exert myself a lot

B. I become short of breath when I hurry or walk up a small hill

C. I walk slower than others my age due to my shortness of breath, or I have to stop to catch my breath when walking on even terrain

D. I stop to catch my breath after about 100 metres or a few minutes of walking

E. I have too much shortness of breath to leave my home, or I get short of breath when getting (un)dressed

	A	B	C	D	E	Don't know
Generally before the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>	(99) <input type="checkbox"/>
Around the test date	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>	(99) <input type="checkbox"/>
1-2 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>	(99) <input type="checkbox"/>
2-6 months following the test	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>	(99) <input type="checkbox"/>
In the past 14 days	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(3) <input type="checkbox"/>	(4) <input type="checkbox"/>	(5) <input type="checkbox"/>	(99) <input type="checkbox"/>

[Only participants indicating having had other symptoms]:

Which other symptoms have you had and when?

[Only participants indicating having had other symptoms]:

Did you also used to have these symptoms generally (i.e. chronically or often) before the test on [test date]?

[test-positives only]:

Did your health return to normal within 4 weeks of testing positive for COVID-19?

- (0) No, my health at this time was not yet completely back to as it was before I became ill
- (1) Yes, my health returned to normal a number of days after symptoms started (write the number of days in the field below) _____
- (99) Don't know

Did you take sick leave around the time of the test on [test date], or any time since then?

Please mark all of the relevant answers, regardless of the cause of illness

- (1) Yes, I was on sick leave in the week up to the test or up to 4 weeks after
- (2) Yes, I was on sick leave more than 4 weeks after the test
- (0) No
- (3) Not relevant

[Only shown for participants, who indicated taking sick leave around the test date]:

How long were you on sick leave in the period around the test?

Think about the period from one week before the test on [test date] and up to 4 weeks after.

Please write the number of sick days in the box below. If you can't remember the exact number, write an approximate amount of days. Have you not been on sick leave, please write '0' in the boxes below.

Full-time sick leave:

Part-time sick leave:

[Only shown for participants, who indicated taking sick leave later than 4 weeks after the test date]:

If you were on sick leave later than 4 weeks after the test date, were you on full-time or part-time sick leave?

If you have been on both full-time and part-time sick leave, please mark both answers below

- (1) Full-time sick leave
- (2) Part-time sick leave

[test-positives only]:

Was your sick leave related to you having had COVID-19?

- (1) Yes
- (0) No
- (2) Partly
- (99) Don't know

[Only participants, who indicated having been on full-time sick leave]:

How long were you on full-time sick leave?

- (2) Less than 2 weeks
- (4) 2-4 weeks
- (12) 1-2 months
- (24) 2-4 months
- (46) 4-6 months
- (10,000) I have been on full-time sick leave since the test date

[Only participants, who indicated having been on part-time sick leave]:

How long were you on part-time sick leave?

- (2) Less than 2 weeks
- (4) 2-4 weeks
- (12) 1-2 months
- (24) 2-4 months
- (46) 4-6 months
- (10,000) I have been on part-time sick leave since the test date

[Only participants, who replied indicated having been on sick leave]:

Has any of your sick leave been within the past 14 days?

- (1) Yes
- (0) No
- (3) Not relevant

The following pages contain some background questions about your health, education, work and lifestyle.

Please provide your height in cm

If you don't know your height, or do not wish to answer, please click "Next" below.

Please provide your approximate weight in kg.

If you don't know your weight, or do not wish to answer, please click "Next" below

What is your highest level of education?

- (1) Primary/Elementary school (9th–10th grade)
- (2) General secondary education or vocational secondary education
- (3) Vocational training
- (4) Shorter term higher education (1–2 years), e.g. vocational academy
- (5) Medium term higher education (2–4 years), e.g. nursing, primary school teaching, BSc
- (6) Longer term higher education (more than 5 years), e.g. Masters or PhD
- (99) Don't know/None of the above/Do not wish to answer

What is your main occupational status?

- (1) Employed full-time
- (2) Employed part-time
- (3) Self-employed
- (4) Student
- (5) Stay-at-home parent or on parental leave
- (6) Jobseeking/Unemployed
- (7) Benefits recipient
- (8) Long-term sick leave
- (9) Pensioner or early retiree
- (10) Other

Do you smoke or have you previously smoked?

- (1) I've never smoked
- (2) It has been more than 5 years since I smoked
- (3) I have smoked within the past 5 years, but no longer smokes
- (4) I smoke occasionally, e.g. social events
- (5) I smoke daily (fewer than 10 cigarettes/cigars/pipes per day)
- (6) I smoke daily (10 or more cigarettes/cigars/pipes per day)
- (7) I smoke e-cigarettes/I vape

Please indicate how many alcoholic drinks you have on average per week.

One drink is for example 1 beer (330ml), 1 glass of wine (120ml), 1 glass of fortified wine (80ml), or 1 shot of spirits (40ml).

If you don't know, or don't wish to answer, please click "Next" below.

If you look at the six months before the test on [test date], what would you say best describes your level of physical activity in your spare time?

- (1) Train hard and play competitive sports regularly, several times a week
- (2) Work out or do heavy gardening or similar at least 4 times a week
- (3) Walk, cycle or other light exercise at least 4 times a week (including leisure walks, light gardening, and cycling/walking to work)
- (4) Read, watch TV or other sedentary lifestyle

If you look at the six months before the test on [test date], how would you describe your physical fitness?

- (1) Really good
- (2) Good
- (3) Fair
- (4) Less good
- (5) Poor

In the period six months before the test on [test date] and up to now, have you had any of the following problems?

Please mark all the relevant answers

	Yes, before the test date	Yes, after the test date	No	Don't know
Difficulties concentrating	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Issues with memory	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Mental exhaustion	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Physical exhaustion	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>
Sleep problems	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>	(99) <input type="checkbox"/>

Have you ever been diagnosed by a doctor with any of the following conditions?

	Yes, before the test date	Yes, after the test date	No
Depression	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>
Anxiety	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>
PTSD (Post traumatic stress disorder)	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>
Chronic fatigue syndrome	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>
Fibromyalgia	(1) <input type="checkbox"/>	(2) <input type="checkbox"/>	(0) <input type="checkbox"/>

Before the test on [test date], were you diagnosed with any chronic disease(s)?

Please mark all relevant.

- (1) No known chronic diseases
- (2) Diabetes
- (3) Asthma
- (4) High blood pressure
- (5) COPD or other chronic lung disease
- (6) Chronic or frequent headaches, including migraines
- (7) Other chronic diseases
- (8) Do not wish to respond

[Test-negatives only]:

Do you think that you have ever had covid-19?

- (1) Yes
- (0) No
- (99) Don't know

[Test-negatives, replying yes to the previous question]:

Why do you think you probably had covid-19?

Please mark all relevant.

- (1) Antibodies were detected in my blood sample
- (2) I had symptoms and I think it was covid-19
- (3) I had symptoms, and talked to a doctor who thought it was covid-19
- (4) For other reasons

Many thanks for taking the time to complete our questionnaire.

May we contact you again?

- (1) Yes
- (0) No

If you have any further comments, feel free to write them in the box below.

Please, remember to click “Finish”

Table S1: Characteristics of the invited persons, stratified by participation status

	Positive	Negative	p-value
Age group (n,%)			
15-19	2350 (3.9%)	3181 (3.5%)	< 0.0001
20-29	9021 (14.8%)	8958 (9.7%)	
30-39	7979 (13.1%)	9838 (10.7%)	
40-49	11 377 (18.7%)	16 117 (17.5%)	
50-59	14 946 (24.5%)	23 873 (26.0%)	
60-69	9530 (15.6%)	18 975 (20.7%)	
70+	5799 (9.5%)	10 936 (11.9%)	
Obesity (n,%)			
Non-obese	46 256 (75.8%)	68 712 (74.8%)	< 0.0001
Obese	9973 (16.3%)	15 073 (16.4%)	
No information	4773 (7.8%)	8093 (8.8%)	
Charlson comorbidity score (n,%)			
0	53 530 (87.8%)	78 694 (85.7%)	< 0.0001
1	3807 (6.2%)	6309 (6.9%)	
2 or more	3665 (6.0%)	6875 (7.4%)	
Region (n, %)			
Hovedstaden	26 242 (43.0%)	29 768 (32.4%)	< 0.0001
Midtjylland	11 233 (18.4%)	19 737 (21.5%)	
Syddanmark	9557 (15.7%)	19 134 (20.8%)	
Sjælland	9233 (15.1%)	12 678 (13.8%)	
Nordjylland	4706 (7.7%)	10 504 (11.4%)	
No information	31 (0.1%)	57 (0.1%)	
Origin (n, %)			
Danish	52 622 (86.3%)	84 045 (91.5%)	< 0.0001
Born abroad	7122 (11.7%)	7165 (7.8%)	
Immigrant	1257 (2.1%)	665 (0.7%)	
Comorbidities (n, %)			
Diabetes	2647 (4.3%)	4202 (4.6%)	0.03
Asthma	4579 (7.5%)	6167 (6.7%)	< 0.0001
High blood pressure	8842 (14.5%)	14 903 (16.2%)	< 0.0001
COPD or other chronic lung disease	1187 (1.9%)	2453 (2.7%)	< 0.0001
Chronic headache (including migraine)	2138 (3.5%)	3457 (3.8%)	0.01
Other chronic disease	7968 (13.1%)	14 751 (16.1%)	< 0.0001
Occupation (n, %)			
Non-healthcare worker	54 400 (89.2%)	79 654 (86.7%)	< 0.0001
Healthcare worker	6602 (10.8%)	12 224 (13.3%)	

Table S2: Characteristics of participants, stratified by participation

	Non-participants	Full-participants	Partial-participants	p-value
Test result (n,%)				
Negative	154 085 (59.1%)	91 878 (60.1%)	11 687 (72.5%)	< 0.0001
Positive	106 552 (40.9%)	61 002 (39.9%)	4438 (27.5%)	
Sex (n, %)				
Female	133 489 (51.2%)	93 494 (61.2%)	10 246 (63.5%)	< 0.0001
Male	127 148 (48.8%)	59 386 (38.8%)	5879 (36.5%)	
Age group (n,%)				
15-19	33 372 (12.8%)	5531 (3.6%)	1757 (10.9%)	< 0.0001
20-29	68 006 (26.1%)	17 979 (11.8%)	3025 (18.8%)	
30-39	50 752 (19.5%)	17 817 (11.7%)	2621 (16.3%)	
40-49	47 302 (18.1%)	27 494 (18.0%)	2825 (17.5%)	
50-59	35 868 (13.8%)	38 819 (25.4%)	2866 (17.8%)	
60-69	15 522 (6.0%)	28 505 (18.6%)	1694 (10.5%)	
70+	9815 (3.8%)	16 735 (10.9%)	1337 (8.3%)	
Occupation (n,%)				
Non-healthcare worker	239 173 (91.8%)	134 054 (87.7%)	14 551 (90.2%)	< 0.0001
Healthcare worker	21 464 (8.2%)	18 826 (12.3%)	1574 (9.8%)	
Elderly home (n,%)				
No	258 830 (99.3%)	152 665 (99.9%)	16 060 (99.6%)	< 0.0001
Yes	1807 (0.7%)	215 (0.1%)	65 (0.4%)	
Origin (n,%)				
Danish	198 669 (76.2%)	136 667 (89.4%)	13 097 (81.2%)	< 0.0001
Born abroad	47 158 (18.1%)	14 287 (9.3%)	2536 (15.7%)	
Immigrant	14 797 (5.7%)	1922 (1.3%)	490 (3.0%)	
Region (n,%)				
Hovedstaden	108 575 (41.7%)	56 010 (36.6%)	6216 (38.5%)	< 0.0001
Midtjylland	50 097 (19.2%)	30 970 (20.3%)	3293 (20.4%)	
Nordjylland	23 400 (9.0%)	15 210 (9.9%)	1580 (9.8%)	
Sjælland	33 807 (13.0%)	21 911 (14.3%)	2094 (13.0%)	
Syddanmark	44 522 (17.1%)	28 691 (18.8%)	2933 (18.2%)	
NA	236 (0.1%)	88 (0.1%)	9 (0.1%)	
Hospitalization due to COVID-19 n,%)				
No	257 488 (98.8%)	150 379 (98.4%)	15 814 (98.1%)	< 0.0001
Yes	3149 (1.2%)	2501 (1.6%)	311 (1.9%)	

Note: Charlson comorbidity scores were based on data from the Danish National Patient Register, whereas the listed comorbidities were self-reported.

Table S3: Risk differences for post-acute symptoms reported after six, nine or twelve months, comparison of SARS-CoV-2 test-positive and test-negative participants

Symptom	6 months after test (n = 22 541)			9 months after test (n = 106 611)			12 months after test (n = 23 728)		
	Positive (n,%)	Negative (n,%)	RD (95% CI)	Positive (n,%)	Negative (n,%)	RD (95% CI)	Positive (n,%)	Negative (n,%)	RD (95% CI)
Dysosmia	702 (9.4%)	70 (0.5%)	9.38 (8.66, 10.20)	5044 (11.5%)	422 (0.7%)	11.56 (11.24, 11.89)	928 (9.5%)	112 (0.8%)	9.26 (8.61, 9.92)
Dysgeusia	587 (7.8%)	59 (0.4%)	7.78 (7.13, 8.44)	4008 (9.2%)	391 (0.6%)	9.06 (8.76, 9.36)	770 (7.9%)	101 (0.7%)	7.65 (7.05, 8.28)
Fatigue/exhaustion	920 (12.3%)	435 (2.9%)	9.79 (8.92, 10.66)	4905 (11.2%)	1959 (3.1%)	8.49 (8.14, 8.86)	974 (9.9%)	474 (3.4%)	6.95 (6.24, 7.77)
Dyspnea	450 (6.0%)	122 (0.8%)	5.70 (5.09, 6.29)	2361 (5.4%)	556 (0.9%)	4.86 (4.61, 5.12)	466 (4.8%)	135 (1.0%)	4.19 (3.73, 4.69)
Reduced strength legs/arms	448 (6.0%)	140 (0.9%)	5.21 (4.57, 5.83)	2448 (5.6%)	715 (1.1%)	4.71 (4.46, 5.00)	485 (5.0%)	169 (1.2%)	4.04 (3.53, 4.58)
Sleeping legs/arms	355 (4.7%)	174 (1.2%)	3.67 (3.12, 4.23)	2053 (4.7%)	859 (1.4%)	3.53 (3.29, 3.78)	433 (4.4%)	203 (1.5%)	3.21 (2.68, 3.74)
Muscle/joint pain	429 (5.7%)	263 (1.7%)	4.05 (3.44, 4.73)	2304 (5.3%)	1236 (2.0%)	3.41 (3.15, 3.67)	484 (4.9%)	273 (2.0%)	3.17 (2.64, 3.75)
Headache	502 (6.7%)	413 (2.7%)	4.05 (3.36, 4.79)	2657 (6.1%)	2003 (3.2%)	2.93 (2.63, 3.25)	581 (5.9%)	452 (3.2%)	2.69 (2.11, 3.30)
Dizziness	322 (4.3%)	210 (1.4%)	2.86 (2.33, 3.45)	1754 (4.0%)	1049 (1.7%)	2.38 (2.15, 2.61)	354 (3.6%)	236 (1.7%)	1.91 (1.45, 2.42)
Chest pain	234 (3.1%)	90 (0.6%)	2.54 (2.13, 3.00)	1195 (2.7%)	538 (0.9%)	1.97 (1.79, 2.15)	266 (2.7%)	152 (1.1%)	1.72 (1.34, 2.13)
Hot flushes/sweat	264 (3.5%)	225 (1.5%)	2.04 (1.52, 2.57)	1474 (3.4%)	1085 (1.7%)	1.63 (1.42, 1.85)	309 (3.2%)	240 (1.7%)	1.49 (1.03, 1.99)
Reduced appetite	242 (3.2%)	153 (1.0%)	2.08 (1.64, 2.54)	1251 (2.9%)	815 (1.3%)	1.45 (1.26, 1.65)	279 (2.8%)	208 (1.5%)	1.32 (0.90, 1.75)
Chills	117 (1.6%)	134 (0.9%)	0.51 (0.18, 0.85)	702 (1.6%)	666 (1.1%)	0.48 (0.33, 0.63)	147 (1.5%)	180 (1.3%)	0.15 (-0.20, 0.49)
Red runny eyes	92 (1.2%)	97 (0.6%)	0.58 (0.30, 0.91)	583 (1.3%)	512 (0.8%)	0.48 (0.34, 0.61)	147 (1.5%)	139 (1.0%)	0.56 (0.26, 0.92)
Nausea	136 (1.8%)	166 (1.1%)	0.59 (0.22, 0.98)	846 (1.9%)	915 (1.5%)	0.41 (0.25, 0.59)	197 (2.0%)	213 (1.5%)	0.42 (0.04, 0.80)
Abdominal pain	156 (2.1%)	192 (1.3%)	0.83 (0.41, 1.25)	877 (2.0%)	1005 (1.6%)	0.35 (0.18, 0.54)	208 (2.1%)	213 (1.5%)	0.51 (0.13, 0.89)
Diarrhoea	119 (1.6%)	190 (1.3%)	0.23 (-0.11, 0.57)	830 (1.9%)	962 (1.5%)	0.32 (0.14, 0.51)	173 (1.8%)	186 (1.3%)	0.53 (0.17, 0.88)
Fever	172 (2.3%)	206 (1.4%)	0.69 (0.28, 1.13)	978 (2.2%)	1120 (1.8%)	0.27 (0.07, 0.47)	212 (2.2%)	258 (1.9%)	0.15 (-0.24, 0.56)
Cough	349 (4.6%)	592 (3.9%)	0.34 (-0.25, 0.96)	2097 (4.8%)	2789 (4.4%)	-0.02 (-0.29, 0.25)	510 (5.2%)	696 (5.0%)	-0.25 (-0.95, 0.36)
Runny nose	267 (3.6%)	527 (3.5%)	-0.26 (-0.80, 0.27)	1710 (3.9%)	2373 (3.8%)	-0.16 (-0.44, 0.09)	399 (4.1%)	574 (4.1%)	-0.41 (-0.96, 0.19)
Sore throat	276 (3.7%)	519 (3.5%)	-0.16 (-0.75, 0.45)	1602 (3.7%)	2583 (4.1%)	-0.79 (-1.04, -0.52)	404 (4.1%)	588 (4.2%)	-0.47 (-1.09, 0.17)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group

(page 1 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Abdominal pain	15-19	49 (3.2%)	69 (3.2%)	0.08 (-1.21, 1.45)	9 (1.1%)	22 (2.2%)	-1.25 (-2.54, 0.09)
	20-29	179 (3.0%)	198 (3.2%)	-0.09 (-0.74, 0.55)	55 (1.8%)	40 (1.5%)	0.34 (-0.38, 1.08)
	30-39	162 (3.3%)	216 (3.3%)	0.03 (-0.61, 0.74)	56 (1.9%)	51 (1.6%)	0.34 (-0.35, 1.06)
	40-49	180 (2.6%)	218 (2.0%)	0.55 (0.10, 1.02)	69 (1.6%)	72 (1.4%)	0.24 (-0.27, 0.76)
	50-59	226 (2.6%)	251 (1.6%)	0.99 (0.62, 1.38)	72 (1.1%)	70 (0.8%)	0.29 (-0.01, 0.62)
	60-69	98 (1.9%)	107 (1.0%)	0.91 (0.51, 1.30)	44 (1.0%)	44 (0.6%)	0.39 (0.09, 0.69)
	70+	23 (0.8%)	30 (0.6%)	0.22 (-0.13, 0.60)	19 (0.6%)	22 (0.4%)	0.21 (-0.06, 0.53)
Dyspnea	15-19	53 (3.5%)	34 (1.6%)	2.37 (1.09, 3.65)	13 (1.6%)	10 (1.0%)	0.71 (-0.54, 1.94)
	20-29	252 (4.3%)	80 (1.3%)	3.48 (2.81, 4.16)	84 (2.7%)	23 (0.9%)	2.22 (1.40, 2.97)
	30-39	305 (6.1%)	77 (1.2%)	5.35 (4.60, 6.10)	123 (4.1%)	23 (0.7%)	3.77 (2.98, 4.63)
	40-49	509 (7.2%)	117 (1.1%)	6.25 (5.61, 6.90)	250 (5.8%)	48 (0.9%)	5.08 (4.37, 5.89)
	50-59	614 (7.2%)	171 (1.1%)	5.94 (5.37, 6.51)	376 (5.9%)	71 (0.8%)	4.98 (4.36, 5.55)
	60-69	303 (6.0%)	68 (0.6%)	5.04 (4.44, 5.68)	235 (5.3%)	49 (0.6%)	4.30 (3.67, 4.95)
	70+	76 (2.7%)	22 (0.4%)	2.10 (1.49, 2.68)	84 (2.8%)	20 (0.4%)	2.22 (1.64, 2.79)
Chest pain	15-19	57 (3.8%)	32 (1.5%)	2.62 (1.43, 3.98)	14 (1.7%)	10 (1.0%)	0.78 (-0.38, 2.05)
	20-29	214 (3.6%)	85 (1.4%)	2.57 (1.97, 3.21)	69 (2.2%)	29 (1.1%)	1.30 (0.48, 2.01)
	30-39	182 (3.7%)	75 (1.1%)	2.79 (2.13, 3.50)	85 (2.8%)	41 (1.3%)	1.74 (1.00, 2.52)
	40-49	279 (4.0%)	127 (1.2%)	2.90 (2.36, 3.41)	107 (2.5%)	42 (0.8%)	1.72 (1.19, 2.28)
	50-59	286 (3.3%)	133 (0.9%)	2.46 (2.06, 2.89)	154 (2.4%)	59 (0.7%)	1.64 (1.26, 2.05)
	60-69	104 (2.1%)	68 (0.6%)	1.35 (0.97, 1.75)	87 (1.9%)	48 (0.6%)	1.20 (0.81, 1.61)
	70+	24 (0.8%)	13 (0.2%)	0.53 (0.24, 0.86)	33 (1.1%)	18 (0.3%)	0.67 (0.34, 1.03)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 2 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Chills	15-19	41 (2.7%)	45 (2.1%)	0.72 (-0.53, 1.85)	6 (0.7%)	16 (1.6%)	-0.96 (-2.04, 0.04)
	20-29	140 (2.4%)	127 (2.0%)	0.41 (-0.17, 1.01)	37 (1.2%)	35 (1.3%)	-0.11 (-0.80, 0.53)
	30-39	122 (2.5%)	141 (2.1%)	0.35 (-0.22, 0.96)	52 (1.7%)	59 (1.8%)	-0.07 (-0.77, 0.61)
	40-49	147 (2.1%)	156 (1.4%)	0.65 (0.23, 1.08)	51 (1.2%)	57 (1.1%)	0.10 (-0.34, 0.52)
	50-59	164 (1.9%)	173 (1.1%)	0.78 (0.45, 1.10)	76 (1.2%)	53 (0.6%)	0.54 (0.25, 0.85)
	60-69	46 (0.9%)	60 (0.5%)	0.34 (0.08, 0.62)	43 (1.0%)	29 (0.4%)	0.54 (0.25, 0.84)
	70+	22 (0.8%)	17 (0.3%)	0.41 (0.09, 0.77)	19 (0.6%)	12 (0.2%)	0.37 (0.10, 0.66)
Cough	15-19	152 (10.1%)	244 (11.3%)	-1.32 (-3.49, 0.80)	55 (6.6%)	100 (9.8%)	-3.49 (-6.02, -0.92)
	20-29	399 (6.8%)	540 (8.6%)	-1.86 (-2.85, -0.89)	181 (5.8%)	180 (6.7%)	-0.92 (-2.22, 0.42)
	30-39	273 (5.5%)	387 (5.9%)	-0.36 (-1.21, 0.49)	169 (5.6%)	171 (5.2%)	0.41 (-0.73, 1.58)
	40-49	363 (5.2%)	590 (5.5%)	-0.33 (-1.00, 0.34)	171 (3.9%)	247 (4.6%)	-0.73 (-1.57, 0.14)
	50-59	441 (5.2%)	642 (4.2%)	0.98 (0.41, 1.54)	261 (4.1%)	277 (3.3%)	0.76 (0.16, 1.37)
	60-69	204 (4.0%)	316 (2.8%)	1.15 (0.52, 1.74)	117 (2.6%)	196 (2.5%)	0.10 (-0.43, 0.68)
	70+	89 (3.2%)	102 (1.9%)	1.19 (0.45, 1.92)	81 (2.7%)	85 (1.5%)	1.15 (0.52, 1.79)
Diarrhoea	15-19	31 (2.1%)	40 (1.8%)	0.25 (-0.79, 1.32)	13 (1.6%)	19 (1.9%)	-0.36 (-1.75, 0.90)
	20-29	136 (2.3%)	158 (2.5%)	-0.19 (-0.84, 0.40)	55 (1.8%)	44 (1.6%)	0.18 (-0.57, 0.91)
	30-39	147 (3.0%)	183 (2.8%)	0.22 (-0.48, 0.85)	69 (2.3%)	48 (1.5%)	0.91 (0.15, 1.64)
	40-49	166 (2.4%)	177 (1.6%)	0.73 (0.31, 1.20)	65 (1.5%)	89 (1.7%)	-0.19 (-0.71, 0.31)
	50-59	199 (2.3%)	218 (1.4%)	0.89 (0.53, 1.28)	80 (1.2%)	82 (1.0%)	0.27 (-0.08, 0.60)
	60-69	74 (1.5%)	128 (1.1%)	0.28 (-0.05, 0.64)	43 (1.0%)	75 (1.0%)	0.00 (-0.30, 0.32)
	70+	25 (0.9%)	39 (0.7%)	0.13 (-0.23, 0.53)	19 (0.6%)	38 (0.7%)	-0.04 (-0.35, 0.29)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 3 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Dizziness	15-19	84 (5.6%)	75 (3.5%)	2.38 (0.84, 3.99)	12 (1.4%)	24 (2.4%)	-1.03 (-2.48, 0.30)
	20-29	305 (5.2%)	218 (3.5%)	1.92 (1.09, 2.69)	70 (2.2%)	55 (2.1%)	0.25 (-0.61, 1.00)
	30-39	321 (6.5%)	197 (3.0%)	3.74 (2.83, 4.61)	98 (3.2%)	55 (1.7%)	1.70 (0.87, 2.55)
	40-49	400 (5.7%)	226 (2.1%)	3.68 (3.05, 4.29)	140 (3.2%)	65 (1.2%)	2.05 (1.42, 2.67)
	50-59	438 (5.1%)	260 (1.7%)	3.42 (2.87, 3.94)	160 (2.5%)	79 (0.9%)	1.53 (1.11, 1.94)
	60-69	164 (3.2%)	119 (1.1%)	2.06 (1.56, 2.58)	108 (2.4%)	52 (0.7%)	1.62 (1.17, 2.07)
	70+	64 (2.3%)	33 (0.6%)	1.51 (0.98, 2.05)	66 (2.2%)	37 (0.7%)	1.38 (0.88, 1.90)
Fatigue/exhaustion	15-19	179 (11.8%)	108 (5.0%)	7.37 (5.41, 9.49)	53 (6.3%)	46 (4.5%)	1.98 (-0.32, 4.25)
	20-29	651 (11.1%)	339 (5.4%)	5.99 (5.00, 7.02)	215 (6.9%)	125 (4.7%)	2.41 (1.13, 3.72)
	30-39	764 (15.4%)	310 (4.7%)	10.93 (9.74, 12.11)	277 (9.2%)	123 (3.8%)	5.61 (4.37, 6.85)
	40-49	1061 (15.1%)	459 (4.3%)	10.84 (9.94, 11.79)	510 (11.8%)	208 (3.9%)	7.93 (6.84, 9.12)
	50-59	1218 (14.3%)	501 (3.2%)	10.91 (10.11, 11.74)	692 (10.8%)	216 (2.6%)	8.17 (7.28, 8.92)
	60-69	525 (10.4%)	212 (1.9%)	8.29 (7.47, 9.15)	359 (8.0%)	118 (1.5%)	6.35 (5.56, 7.19)
	70+	149 (5.3%)	52 (1.0%)	4.24 (3.41, 5.09)	146 (4.9%)	51 (0.9%)	3.92 (3.10, 4.75)
Fever	15-19	59 (3.9%)	98 (4.5%)	-0.66 (-2.01, 0.83)	24 (2.9%)	31 (3.0%)	-0.19 (-1.86, 1.53)
	20-29	225 (3.8%)	240 (3.8%)	0.03 (-0.72, 0.73)	75 (2.4%)	78 (2.9%)	-0.51 (-1.37, 0.31)
	30-39	157 (3.2%)	200 (3.0%)	0.14 (-0.49, 0.82)	90 (3.0%)	73 (2.2%)	0.82 (-0.01, 1.66)
	40-49	169 (2.4%)	224 (2.1%)	0.32 (-0.18, 0.77)	87 (2.0%)	94 (1.8%)	0.24 (-0.32, 0.78)
	50-59	196 (2.3%)	259 (1.7%)	0.60 (0.23, 0.98)	110 (1.7%)	90 (1.1%)	0.64 (0.25, 1.02)
	60-69	60 (1.2%)	111 (1.0%)	0.17 (-0.16, 0.50)	57 (1.3%)	53 (0.7%)	0.56 (0.24, 0.92)
	70+	22 (0.8%)	19 (0.4%)	0.39 (0.06, 0.77)	31 (1.0%)	14 (0.2%)	0.72 (0.39, 1.08)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 4 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Headache	15-19	121 (8.0%)	120 (5.5%)	2.59 (0.99, 4.33)	34 (4.1%)	51 (5.0%)	-0.99 (-2.96, 0.86)
	20-29	460 (7.8%)	329 (5.2%)	2.68 (1.80, 3.63)	163 (5.2%)	129 (4.8%)	0.44 (-0.70, 1.59)
	30-39	504 (10.2%)	326 (5.0%)	5.26 (4.28, 6.17)	206 (6.8%)	135 (4.1%)	2.77 (1.53, 3.92)
	40-49	599 (8.5%)	421 (3.9%)	4.59 (3.86, 5.33)	265 (6.1%)	200 (3.8%)	2.37 (1.49, 3.28)
	50-59	657 (7.7%)	482 (3.1%)	4.52 (3.90, 5.16)	244 (3.8%)	219 (2.6%)	1.21 (0.62, 1.82)
	60-69	241 (4.8%)	223 (2.0%)	2.71 (2.07, 3.39)	146 (3.3%)	138 (1.8%)	1.48 (0.91, 2.10)
	70+	59 (2.1%)	58 (1.1%)	0.99 (0.40, 1.59)	41 (1.4%)	37 (0.7%)	0.71 (0.24, 1.19)
Hot flushes/sweat	15-19	66 (4.4%)	71 (3.3%)	1.24 (-0.13, 2.66)	17 (2.0%)	21 (2.1%)	-0.02 (-1.41, 1.52)
	20-29	253 (4.3%)	229 (3.6%)	0.75 (0.01, 1.47)	63 (2.0%)	49 (1.8%)	0.24 (-0.53, 1.01)
	30-39	227 (4.6%)	188 (2.9%)	1.83 (1.15, 2.57)	90 (3.0%)	71 (2.2%)	0.89 (0.06, 1.73)
	40-49	358 (5.1%)	261 (2.4%)	2.70 (2.13, 3.29)	118 (2.7%)	98 (1.8%)	0.90 (0.28, 1.53)
	50-59	386 (4.5%)	228 (1.5%)	2.98 (2.53, 3.47)	161 (2.5%)	98 (1.2%)	1.33 (0.89, 1.75)
	60-69	152 (3.0%)	120 (1.1%)	1.83 (1.34, 2.34)	74 (1.7%)	67 (0.9%)	0.75 (0.36, 1.14)
	70+	48 (1.7%)	29 (0.5%)	1.08 (0.63, 1.59)	34 (1.1%)	20 (0.4%)	0.73 (0.34, 1.13)
Dysosmia	15-19	207 (13.7%)	52 (2.4%)	11.77 (9.80, 13.72)	83 (9.9%)	18 (1.8%)	8.46 (6.08, 10.72)
	20-29	854 (14.5%)	77 (1.2%)	13.60 (12.61, 14.61)	401 (12.8%)	17 (0.6%)	12.57 (11.3, 13.82)
	30-39	743 (15.0%)	64 (1.0%)	14.13 (13.07, 15.19)	370 (12.3%)	23 (0.7%)	11.84 (10.65, 13.13)
	40-49	1057 (15.0%)	106 (1.0%)	14.01 (13.14, 14.90)	484 (11.2%)	38 (0.7%)	10.55 (9.62, 11.62)
	50-59	1068 (12.5%)	92 (0.6%)	11.79 (11.07, 12.49)	531 (8.3%)	40 (0.5%)	7.80 (7.11, 8.47)
	60-69	407 (8.0%)	39 (0.3%)	7.54 (6.78, 8.31)	269 (6.0%)	19 (0.2%)	5.69 (4.95, 6.38)
	70+	109 (3.9%)	9 (0.2%)	3.66 (2.99, 4.42)	91 (3.1%)	10 (0.2%)	2.85 (2.27, 3.49)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 5 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Dysgeusia	15-19	155 (10.3%)	27 (1.2%)	9.56 (7.87, 11.23)	59 (7.0%)	5 (0.5%)	6.97 (5.25, 8.92)
	20-29	635 (10.8%)	64 (1.0%)	10.19 (9.30, 11.09)	303 (9.7%)	18 (0.7%)	9.54 (8.38, 10.74)
	30-39	591 (11.9%)	63 (1.0%)	11.21 (10.26, 12.31)	273 (9.0%)	19 (0.6%)	8.85 (7.68, 10.01)
	40-49	858 (12.2%)	107 (1.0%)	11.26 (10.51, 11.97)	378 (8.7%)	34 (0.6%)	8.25 (7.39, 9.16)
	50-59	917 (10.7%)	88 (0.6%)	10.05 (9.42, 10.75)	428 (6.7%)	37 (0.4%)	6.24 (5.65, 6.88)
	60-69	348 (6.9%)	46 (0.4%)	6.26 (5.57, 6.96)	221 (5.0%)	20 (0.3%)	4.56 (3.93, 5.22)
	70+	114 (4.0%)	15 (0.3%)	3.60 (2.90, 4.32)	85 (2.9%)	8 (0.1%)	2.58 (2.03, 3.20)
Muscle/joint pain	15-19	64 (4.2%)	74 (3.4%)	0.89 (-0.42, 2.23)	15 (1.8%)	14 (1.4%)	0.46 (-0.71, 1.64)
	20-29	293 (5.0%)	218 (3.5%)	1.61 (0.86, 2.35)	96 (3.1%)	68 (2.5%)	0.59 (-0.27, 1.53)
	30-39	363 (7.3%)	238 (3.6%)	3.79 (2.91, 4.61)	150 (5.0%)	99 (3.0%)	2.02 (0.97, 3.08)
	40-49	525 (7.5%)	291 (2.7%)	4.76 (4.08, 5.39)	217 (5.0%)	115 (2.2%)	2.88 (2.14, 3.64)
	50-59	606 (7.1%)	266 (1.7%)	5.30 (4.72, 5.92)	331 (5.2%)	123 (1.5%)	3.68 (3.11, 4.29)
	60-69	241 (4.8%)	113 (1.0%)	3.66 (3.04, 4.29)	180 (4.0%)	87 (1.1%)	2.84 (2.27, 3.44)
	70+	63 (2.2%)	29 (0.5%)	1.66 (1.08, 2.28)	73 (2.5%)	37 (0.7%)	1.74 (1.22, 2.31)
Nausea	15-19	57 (3.8%)	70 (3.2%)	0.66 (-0.75, 2.09)	10 (1.2%)	19 (1.9%)	-0.80 (-2.11, 0.45)
	20-29	223 (3.8%)	216 (3.4%)	0.44 (-0.31, 1.23)	45 (1.4%)	33 (1.2%)	0.28 (-0.43, 0.99)
	30-39	163 (3.3%)	214 (3.3%)	0.08 (-0.69, 0.85)	52 (1.7%)	58 (1.8%)	-0.03 (-0.76, 0.68)
	40-49	178 (2.5%)	197 (1.8%)	0.72 (0.25, 1.19)	42 (1.0%)	49 (0.9%)	0.04 (-0.35, 0.49)
	50-59	203 (2.4%)	214 (1.4%)	0.96 (0.61, 1.35)	59 (0.9%)	44 (0.5%)	0.39 (0.10, 0.65)
	60-69	72 (1.4%)	110 (1.0%)	0.39 (0.03, 0.77)	30 (0.7%)	29 (0.4%)	0.27 (0.02, 0.51)
	70+	31 (1.1%)	25 (0.5%)	0.55 (0.18, 0.94)	14 (0.5%)	16 (0.3%)	0.15 (-0.08, 0.38)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 6 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Red runny eyes	15-19	27 (1.8%)	54 (2.5%)	-0.78 (-1.78, 0.22)	6 (0.7%)	19 (1.9%)	-1.26 (-2.38, -0.16)
	20-29	94 (1.6%)	92 (1.5%)	0.15 (-0.32, 0.63)	35 (1.1%)	20 (0.7%)	0.42 (-0.12, 0.94)
	30-39	88 (1.8%)	82 (1.2%)	0.57 (0.08, 1.10)	40 (1.3%)	27 (0.8%)	0.55 (0.02, 1.09)
	40-49	137 (1.9%)	113 (1.0%)	0.92 (0.54, 1.32)	39 (0.9%)	31 (0.6%)	0.31 (-0.05, 0.67)
	50-59	155 (1.8%)	126 (0.8%)	0.98 (0.65, 1.28)	63 (1.0%)	57 (0.7%)	0.29 (0.00, 0.58)
	60-69	59 (1.2%)	53 (0.5%)	0.65 (0.32, 0.95)	38 (0.9%)	41 (0.5%)	0.30 (0.01, 0.59)
	70+	20 (0.7%)	15 (0.3%)	0.38 (0.09, 0.70)	21 (0.7%)	18 (0.3%)	0.33 (0.05, 0.66)
Reduced appetite	15-19	115 (7.6%)	71 (3.3%)	4.89 (3.24, 6.62)	32 (3.8%)	15 (1.5%)	2.63 (1.10, 4.28)
	20-29	297 (5.0%)	200 (3.2%)	2.08 (1.30, 2.81)	89 (2.8%)	37 (1.4%)	1.68 (0.91, 2.43)
	30-39	215 (4.3%)	173 (2.6%)	1.86 (1.11, 2.61)	73 (2.4%)	43 (1.3%)	1.24 (0.51, 2.01)
	40-49	222 (3.2%)	181 (1.7%)	1.53 (1.03, 2.04)	86 (2.0%)	53 (1.0%)	1.03 (0.52, 1.56)
	50-59	239 (2.8%)	164 (1.1%)	1.72 (1.35, 2.11)	116 (1.8%)	53 (0.6%)	1.17 (0.79, 1.52)
	60-69	101 (2.0%)	90 (0.8%)	1.11 (0.73, 1.54)	62 (1.4%)	35 (0.4%)	0.86 (0.54, 1.21)
	70+	70 (2.5%)	33 (0.6%)	1.63 (1.10, 2.17)	55 (1.8%)	28 (0.5%)	1.14 (0.73, 1.64)
Reduced strength legs/arms	15-19	50 (3.3%)	39 (1.8%)	1.75 (0.54, 2.95)	17 (2.0%)	5 (0.5%)	1.76 (0.61, 3.03)
	20-29	195 (3.3%)	84 (1.3%)	2.25 (1.64, 2.85)	84 (2.7%)	21 (0.8%)	2.17 (1.47, 2.92)
	30-39	294 (5.9%)	112 (1.7%)	4.63 (3.81, 5.41)	140 (4.6%)	48 (1.5%)	3.43 (2.58, 4.36)
	40-49	488 (6.9%)	147 (1.4%)	5.79 (5.16, 6.43)	237 (5.5%)	79 (1.5%)	4.03 (3.27, 4.80)
	50-59	673 (7.9%)	195 (1.3%)	6.63 (6.03, 7.25)	421 (6.6%)	86 (1.0%)	5.34 (4.67, 5.95)
	60-69	315 (6.2%)	75 (0.7%)	5.32 (4.68, 6.02)	234 (5.2%)	56 (0.7%)	4.09 (3.51, 4.68)
	70+	104 (3.7%)	36 (0.7%)	2.71 (2.03, 3.38)	129 (4.3%)	41 (0.7%)	3.11 (2.42, 3.83)

Table S4: Risk differences of symptoms after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 7 of 7)

Symptom	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Runny nose	15-19	122 (8.1%)	206 (9.5%)	-1.52 (-3.39, 0.43)	41 (4.9%)	87 (8.5%)	-3.82 (-6.18, -1.53)
	20-29	368 (6.3%)	478 (7.6%)	-1.39 (-2.29, -0.45)	145 (4.6%)	148 (5.5%)	-0.89 (-2.08, 0.36)
	30-39	250 (5.0%)	389 (5.9%)	-0.89 (-1.73, -0.02)	122 (4.0%)	140 (4.3%)	-0.22 (-1.21, 0.77)
	40-49	285 (4.0%)	504 (4.7%)	-0.66 (-1.23, -0.06)	157 (3.6%)	217 (4.1%)	-0.47 (-1.20, 0.32)
	50-59	348 (4.1%)	536 (3.5%)	0.58 (0.04, 1.06)	175 (2.7%)	213 (2.5%)	0.19 (-0.30, 0.75)
	60-69	157 (3.1%)	249 (2.2%)	0.83 (0.37, 1.40)	107 (2.4%)	151 (1.9%)	0.44 (-0.11, 0.97)
	70+	51 (1.8%)	71 (1.3%)	0.44 (-0.14, 1.03)	48 (1.6%)	85 (1.5%)	0.09 (-0.41, 0.65)
Sleeping legs/arms	15-19	54 (3.6%)	41 (1.9%)	1.91 (0.68, 3.14)	12 (1.4%)	10 (1.0%)	0.51 (-0.61, 1.60)
	20-29	193 (3.3%)	123 (2.0%)	1.49 (0.88, 2.12)	71 (2.3%)	38 (1.4%)	0.99 (0.25, 1.82)
	30-39	301 (6.1%)	147 (2.2%)	4.11 (3.34, 4.90)	122 (4.0%)	45 (1.4%)	2.90 (2.05, 3.82)
	40-49	475 (6.7%)	201 (1.9%)	4.99 (4.39, 5.66)	169 (3.9%)	72 (1.4%)	2.60 (1.91, 3.33)
	50-59	557 (6.5%)	228 (1.5%)	4.98 (4.37, 5.54)	297 (4.6%)	81 (1.0%)	3.59 (3.05, 4.14)
	60-69	255 (5.0%)	109 (1.0%)	3.85 (3.26, 4.41)	167 (3.7%)	68 (0.9%)	2.65 (2.14, 3.22)
	70+	81 (2.9%)	35 (0.7%)	2.02 (1.43, 2.65)	87 (2.9%)	38 (0.7%)	2.01 (1.40, 2.58)
Sore throat	15-19	128 (8.5%)	223 (10.3%)	-1.96 (-3.95, -0.02)	41 (4.9%)	97 (9.5%)	-4.93 (-7.47, -2.54)
	20-29	384 (6.5%)	518 (8.3%)	-1.77 (-2.77, -0.78)	146 (4.7%)	156 (5.8%)	-1.16 (-2.26, 0.12)
	30-39	242 (4.9%)	387 (5.9%)	-1.00 (-1.78, -0.17)	112 (3.7%)	145 (4.4%)	-0.72 (-1.70, 0.22)
	40-49	324 (4.6%)	613 (5.7%)	-1.10 (-1.75, -0.43)	135 (3.1%)	195 (3.7%)	-0.57 (-1.25, 0.17)
	50-59	341 (4.0%)	608 (3.9%)	0.04 (-0.46, 0.56)	146 (2.3%)	192 (2.3%)	-0.01 (-0.51, 0.45)
	60-69	138 (2.7%)	296 (2.7%)	0.05 (-0.46, 0.57)	65 (1.5%)	130 (1.7%)	-0.20 (-0.63, 0.22)
	70+	43 (1.5%)	80 (1.5%)	0.00 (-0.48, 0.55)	37 (1.2%)	50 (0.9%)	0.33 (-0.13, 0.79)

Table S5: Risk differences of health problems after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group
(page 1 of 2)

Medical diagnosis	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Difficulties concentrating	15-19	407 (33.0%)	161 (9.6%)	25.16 (22.03, 28.21)	123 (17.1%)	43 (5.1%)	13.32 (10.04, 16.98)
	20-29	1712 (33.8%)	279 (5.4%)	30.19 (28.87, 31.74)	628 (22.5%)	102 (4.5%)	19.83 (17.91, 21.70)
	30-39	1711 (37.9%)	316 (5.5%)	33.70 (32.16, 35.29)	754 (27.0%)	100 (3.4%)	25.20 (23.36, 27.03)
	40-49	2562 (39.5%)	442 (4.7%)	35.55 (34.32, 36.79)	1136 (27.8%)	156 (3.2%)	25.43 (23.97, 26.91)
	50-59	2966 (37.6%)	531 (3.8%)	33.68 (32.49, 34.80)	1638 (26.8%)	206 (2.6%)	24.24 (23.15, 25.40)
	60-69	1324 (27.6%)	197 (1.9%)	24.85 (23.54, 26.11)	926 (21.6%)	130 (1.7%)	19.02 (17.79, 20.22)
	70+	428 (15.7%)	61 (1.2%)	13.58 (12.20, 14.98)	405 (14.2%)	88 (1.6%)	11.46 (10.18, 12.67)
Memory issues	15-19	350 (26.0%)	103 (5.5%)	22.46 (19.68, 25.17)	105 (13.7%)	34 (3.6%)	11.14 (7.96, 14.23)
	20-29	1502 (28.1%)	286 (5.3%)	24.58 (23.12, 25.99)	496 (17.0%)	91 (3.8%)	14.75 (12.99, 16.45)
	30-39	1616 (36.1%)	331 (5.9%)	31.76 (30.22, 33.35)	592 (21.0%)	93 (3.1%)	19.24 (17.51, 21.05)
	40-49	2532 (40.0%)	481 (5.2%)	35.72 (34.34, 37.03)	1072 (26.3%)	175 (3.6%)	23.54 (22.17, 25.09)
	50-59	3075 (39.4%)	583 (4.3%)	35.20 (34.08, 36.46)	1582 (26.0%)	245 (3.1%)	22.84 (21.70, 24.04)
	60-69	1376 (29.0%)	260 (2.5%)	25.65 (24.41, 26.87)	944 (22.5%)	160 (2.2%)	19.27 (18.09, 20.50)
	70+	450 (17.0%)	82 (1.7%)	14.18 (12.84, 15.56)	457 (16.6%)	133 (2.6%)	12.62 (11.32, 14.00)
Mental exhaustion	15-19	537 (46.8%)	280 (18.9%)	29.19 (25.48, 33.05)	176 (24.3%)	82 (9.8%)	15.76 (11.94, 19.56)
	20-29	2228 (46.0%)	634 (14.2%)	33.14 (31.27, 34.90)	796 (28.8%)	251 (11.7%)	18.53 (16.27, 20.63)
	30-39	2047 (47.6%)	638 (12.5%)	36.17 (34.33, 38.04)	941 (34.7%)	227 (8.4%)	27.70 (25.61, 29.80)
	40-49	3049 (48.9%)	920 (10.4%)	39.11 (37.73, 40.48)	1421 (35.7%)	346 (7.5%)	28.97 (27.13, 30.68)
	50-59	3652 (47.0%)	1069 (8.1%)	38.96 (37.76, 40.15)	2089 (34.3%)	457 (6.0%)	28.44 (27.12, 29.92)
	60-69	1737 (36.3%)	474 (4.7%)	30.96 (29.54, 32.37)	1145 (26.8%)	273 (3.7%)	22.30 (21.01, 23.62)
	70+	544 (20.0%)	98 (2.0%)	17.36 (15.78, 18.81)	448 (15.6%)	128 (2.4%)	12.27 (10.92, 13.54)

Table S5: Risk differences of health problems after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 2 of 2)

Medical diagnosis	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Physical exhaustion	15-19	608 (46.4%)	213 (12.2%)	36.32 (33.11, 39.50)	179 (23.2%)	58 (6.5%)	18.47 (14.70, 22.24)
	20-29	2466 (47.3%)	547 (10.6%)	38.42 (36.69, 40.07)	895 (31.0%)	195 (8.4%)	24.67 (22.43, 26.79)
	30-39	2290 (51.4%)	593 (10.9%)	41.81 (40.00, 43.65)	1121 (40.3%)	205 (7.1%)	34.97 (32.87, 37.18)
	40-49	3544 (55.3%)	875 (9.5%)	46.54 (45.16, 47.81)	1798 (44.4%)	330 (6.9%)	38.63 (36.89, 40.32)
	50-59	4302 (54.7%)	1109 (8.2%)	46.74 (45.52, 48.02)	2639 (43.5%)	446 (5.8%)	37.94 (36.57, 39.36)
	60-69	2262 (47.6%)	580 (5.8%)	41.15 (39.79, 42.54)	1663 (39.7%)	335 (4.7%)	34.05 (32.45, 35.43)
	70+	887 (34.1%)	176 (3.7%)	29.34 (27.48, 31.20)	838 (30.5%)	217 (4.2%)	24.64 (22.85, 26.40)
Sleep problems	15-19	292 (23.9%)	193 (11.3%)	13.45 (10.61, 16.43)	112 (15.6%)	60 (7.1%)	9.14 (5.73, 12.53)
	20-29	1054 (21.6%)	425 (8.7%)	13.72 (12.13, 15.22)	431 (15.9%)	168 (7.7%)	9.02 (7.07, 10.90)
	30-39	988 (23.2%)	458 (8.6%)	15.30 (13.77, 16.83)	466 (17.6%)	157 (5.7%)	12.72 (10.91, 14.43)
	40-49	1600 (27.1%)	740 (8.4%)	19.03 (17.79, 20.41)	774 (20.4%)	292 (6.4%)	14.31 (12.81, 15.78)
	50-59	2278 (33.4%)	1006 (8.3%)	23.98 (23.81, 26.14)	1214 (21.3%)	380 (5.2%)	16.02 (14.82, 17.20)
	60-69	1071 (26.0%)	483 (5.4%)	19.96 (18.57, 21.30)	780 (19.4%)	257 (3.7%)	14.92 (13.73, 16.13)
	70+	443 (19.1%)	157 (3.6%)	14.52 (13.14, 16.11)	347 (12.8%)	160 (3.1%)	8.82 (7.57, 10.03)


Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group
(page 1 of 2)

Medical diagnosis	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Depression	15-19	87 (6.2%)	99 (5.1%)	1.16 (-0.47, 2.78)	29 (3.6%)	26 (2.7%)	0.94 (-0.77, 2.70)
	20-29	244 (4.8%)	177 (3.3%)	1.62 (0.81, 2.50)	105 (3.6%)	82 (3.4%)	0.29 (-0.81, 1.36)
	30-39	188 (4.5%)	118 (2.2%)	2.51 (1.73, 3.32)	91 (3.3%)	61 (2.1%)	1.33 (0.38, 2.26)
	40-49	194 (3.2%)	182 (2.0%)	1.26 (0.69, 1.82)	119 (3.0%)	92 (1.9%)	1.10 (0.37, 1.86)
	50-59	227 (3.0%)	284 (2.1%)	0.87 (0.43, 1.30)	174 (2.9%)	180 (2.3%)	0.57 (0.02, 1.14)
	60-69	116 (2.6%)	200 (2.0%)	0.48 (-0.05, 0.97)	119 (2.9%)	158 (2.2%)	0.62 (0.11, 1.17)
	70+	101 (3.9%)	112 (2.3%)	1.38 (0.66, 2.11)	89 (3.2%)	99 (1.8%)	1.08 (0.46, 1.68)
Anxiety	15-19	77 (5.9%)	103 (5.6%)	0.26 (-1.48, 1.97)	24 (3.0%)	18 (1.9%)	1.17 (-0.31, 2.79)
	20-29	310 (6.2%)	174 (3.3%)	3.10 (2.21, 3.98)	114 (3.9%)	70 (2.8%)	1.16 (0.16, 2.23)
	30-39	218 (5.0%)	126 (2.2%)	2.94 (2.08, 3.75)	84 (3.0%)	48 (1.6%)	1.48 (0.59, 2.25)
	40-49	211 (3.3%)	178 (1.8%)	1.53 (1.01, 2.06)	104 (2.5%)	79 (1.6%)	0.98 (0.40, 1.54)
	50-59	237 (3.0%)	274 (1.9%)	1.03 (0.61, 1.46)	150 (2.4%)	154 (1.9%)	0.51 (0.04, 0.96)
	60-69	109 (2.3%)	213 (2.0%)	0.19 (-0.28, 0.67)	99 (2.3%)	158 (2.1%)	0.17 (-0.35, 0.64)
	70+	88 (3.2%)	104 (2.1%)	1.04 (0.38, 1.69)	75 (2.6%)	84 (1.5%)	0.90 (0.32, 1.50)
PTSD	15-19	19 (1.3%)	19 (0.9%)	0.39 (-0.29, 1.16)	6 (0.7%)	7 (0.7%)	0.03 (-0.76, 0.79)
	20-29	52 (0.9%)	38 (0.6%)	0.30 (-0.05, 0.60)	28 (0.9%)	23 (0.9%)	0.05 (-0.48, 0.54)
	30-39	72 (1.5%)	40 (0.6%)	0.91 (0.51, 1.31)	36 (1.2%)	22 (0.7%)	0.55 (0.05, 1.05)
	40-49	95 (1.4%)	103 (1.0%)	0.42 (0.07, 0.77)	57 (1.3%)	63 (1.2%)	0.13 (-0.33, 0.58)
	50-59	116 (1.4%)	200 (1.3%)	0.04 (-0.25, 0.34)	94 (1.5%)	127 (1.5%)	-0.04 (-0.43, 0.38)
	60-69	66 (1.3%)	165 (1.5%)	-0.19 (-0.58, 0.18)	67 (1.5%)	143 (1.9%)	-0.31 (-0.75, 0.13)
	70+	31 (1.1%)	78 (1.5%)	-0.34 (-0.78, 0.09)	30 (1.0%)	72 (1.3%)	-0.25 (-0.62, 0.18)

Table S6: Risk differences of self-reported diagnoses after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group, continued
(page 2 of 2)

Medical diagnosis	Age (years)	Female (n = 93 494)			Male (n = 59 386)		
		Positive (n, %)	Negative (n, %)	RD (95% CI)	Positive (n, %)	Negative (n, %)	RD (95% CI)
Chronic fatigue syndrome	15-19	58 (3.9%)	27 (1.3%)	2.89 (1.75, 4.12)	16 (1.9%)	5 (0.5%)	1.61 (0.56, 2.90)
	20-29	192 (3.3%)	40 (0.6%)	2.98 (2.38, 3.51)	80 (2.6%)	26 (1.0%)	1.86 (1.13, 2.58)
	30-39	209 (4.3%)	39 (0.6%)	4.00 (3.39, 4.66)	101 (3.4%)	27 (0.8%)	2.80 (2.03, 3.57)
	40-49	268 (3.9%)	120 (1.1%)	2.86 (2.35, 3.43)	153 (3.6%)	67 (1.3%)	2.39 (1.71, 3.03)
	50-59	330 (3.9%)	219 (1.4%)	2.46 (2.03, 2.93)	270 (4.3%)	152 (1.8%)	2.42 (1.83, 3.04)
	60-69	198 (4.0%)	208 (1.9%)	1.94 (1.38, 2.54)	203 (4.6%)	174 (2.3%)	2.17 (1.52, 2.77)
	70+	169 (6.1%)	117 (2.3%)	3.25 (2.40, 4.12)	154 (5.3%)	108 (2.0%)	2.81 (2.05, 3.65)
Fibromyalgia	15-19	15 (1.0%)	6 (0.3%)	0.75 (0.22, 1.36)	6 (0.7%)	5 (0.5%)	0.24 (-0.54, 0.99)
	20-29	36 (0.6%)	20 (0.3%)	0.32 (0.06, 0.56)	20 (0.6%)	20 (0.7%)	-0.10 (-0.57, 0.36)
	30-39	44 (0.9%)	30 (0.5%)	0.46 (0.15, 0.80)	27 (0.9%)	21 (0.6%)	0.27 (-0.20, 0.71)
	40-49	77 (1.1%)	92 (0.9%)	0.25 (-0.06, 0.55)	49 (1.1%)	52 (1.0%)	0.15 (-0.25, 0.55)
	50-59	83 (1.0%)	171 (1.1%)	-0.15 (-0.43, 0.12)	85 (1.3%)	114 (1.4%)	-0.02 (-0.41, 0.37)
	60-69	52 (1.0%)	165 (1.5%)	-0.47 (-0.84, -0.11)	60 (1.4%)	138 (1.8%)	-0.41 (-0.81, 0.05)
	70+	40 (1.4%)	80 (1.5%)	-0.10 (-0.62, 0.41)	26 (0.9%)	72 (1.3%)	-0.38 (-0.78, 0.02)

Figure S1: Risk differences of symptoms around the test date, comparing SARS-CoV-2 test-positive and test-negative participants.



Note: “Around the test date” is defined as from one week prior to the test date and until four weeks after. For symptoms around the test date, test-negatives with symptoms as indication for testing are used as control population. Risk differences with 95% confidence intervals were adjusted for age, sex, comorbidities, obesity, healthcare-occupation and time after testing (in months).

Figure S2: Risk differences of symptoms 6-12 months after test, comparing hospitalized and non-hospitalized SARS-CoV-2 test-positive participants.




Figure S3: Risk differences self-reported health problems with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group




Figure S4: Risk differences self-reported diagnoses with new onset from the test date and up to after 6-12 months, comparing SARS-CoV-2 test-positive and test-negative participants, stratified by sex and age group

